NextCure, Inc. (NXTC) vs TScan Therapeutics, Inc. (TCRX)
NextCure, Inc. and TScan Therapeutics, Inc. are both Biotechnology companies. NextCure, Inc. and TScan Therapeutics, Inc. are of similar size ($25.4M and $23.7M). NextCure, Inc. has the higher net margin (0.00% vs −1,655.4%) and the higher return on invested capital (0.00% vs −4,588.2%). Across the 16 metrics below, NextCure, Inc. leads on 11 and TScan Therapeutics, Inc. on 5.
Valuation
Profitability
| Metric | NXTC | TCRX | Biotechnology median |
|---|---|---|---|
| Gross margin | 0.00% | 100.00% | 65.16% |
| Operating margin | 0.00% | (1,695.15%) | 0.00% |
| Net margin | 0.00% | (1,655.35%) | 0.00% |
| Free cash flow margin | 0.00% | (1,665.18%) | 0.00% |
| Return on equity | (195.22%) | (95.80%) | (57.72%) |
| Return on assets | (121.60%) | (50.09%) | (49.22%) |
| Return on invested capital | 0.00% | (4,588.23%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack